Literature DB >> 24506284

Proteinase-activated receptors 1 and 2 and the regulation of porcine coronary artery contractility: a role for distinct tyrosine kinase pathways.

Mahmoud El-Daly1, Mahmoud Saifeddine, Koichiro Mihara, Rithwik Ramachandran, Christopher R Triggle, Morley D Hollenberg.   

Abstract

BACKGROUND AND
PURPOSE: Because angiotensin-II-mediated porcine coronary artery (PCA) vasoconstriction is blocked by protein tyrosine kinase (PYK) inhibitors, we hypothesized that proteinase-activated receptors (PARs), known to regulate vascular tension, like angiotensin-II, would also cause PCA contractions via PYK-dependent signalling pathways. EXPERIMENTAL APPROACH: Contractions of intact and endothelium-free isolated PCA rings, stimulated by PAR1 /PAR2 -activating peptides, angiotensin-II, PGF2α , EGF, PDGF and KCl, were monitored with/without multiple signalling pathway inhibitors, including AG-tyrphostins AG18 (non-specific PYKs), AG1478 (EGF-receptor kinase), AG1296 (PDGF receptor kinase), PP1 (Src kinase), U0126 and PD98059 (MEK/MAPKinase kinase), indomethacin/SC-560/NS-398 (COX-1/2) and L-NAME (NOS). KEY
RESULTS: AG18 inhibited the contractions induced by all the agonists except KCl, whereas U0126 attenuated contractions induced by PAR1 /PAR2 agonists, EGF and angiotensin-II, but not by PGF2α , the COX-produced metabolites of arachidonate and KCl. PP1 only affected the responses to PAR1 /PAR2 -activating peptides and angiotensin-II. The EGF-kinase inhibitor, AG1478, attenuated contractions initiated by the PARs (PAR2 >> PAR1 ) and EGF itself, but not by angiotensin-II, PGF2α or KCl. COX-1/2 inhibitors blocked the contractions induced by all the agonists, except KCl and PGF2α . CONCLUSION AND IMPLICATIONS: PAR1/2 -mediated contractions of the PCA are dependent on Src and MAPKinase and, in part, involve EGF-receptor-kinase transactivation and the generation of a COX-derived contractile agonist. However, the PYK signalling pathways used by PARs are distinct from each other and from those triggered by angiotensin-II and EGF. These signalling pathways may be therapeutic targets for managing coagulation-proteinase-induced coronary vasospasm.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  EGF; MAPKinase; PARs; PGF2α; angiotensin-II; coronary contraction; cyclooxygenase; protease; proteinase-activated receptors; tyrosine kinase signalling pathways

Mesh:

Substances:

Year:  2014        PMID: 24506284      PMCID: PMC3997280          DOI: 10.1111/bph.12593

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  52 in total

1.  Epidermal growth factor-urogastrone (EGF-URO) causes contraction of porcine coronary arterial strips: inhibition by indomethacin.

Authors:  B S Gan; M D Hollenberg; K Lederis
Journal:  Proc West Pharmacol Soc       Date:  1989

Review 2.  Tyrosine kinase inhibition: an approach to drug development.

Authors:  A Levitzki; A Gazit
Journal:  Science       Date:  1995-03-24       Impact factor: 47.728

3.  Vascular actions of thrombin receptor-derived polypeptides: structure-activity profiles for contractile and relaxant effects in rat aorta.

Authors:  A A Laniyonu; M D Hollenberg
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

4.  2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.

Authors:  John J McGuire; Mahmoud Saifeddine; Chris R Triggle; Kimberly Sun; Morley D Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2004-02-19       Impact factor: 4.030

5.  Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation.

Authors:  J H Hanke; J P Gardner; R L Dow; P S Changelian; W H Brissette; E J Weringer; B A Pollok; P A Connelly
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

6.  Tyrosine kinase inhibitors and the contractile action of G-protein-linked vascular agonists.

Authors:  A A Laniyonu; M Saifeddine; S G Yang; M D Hollenberg
Journal:  Can J Physiol Pharmacol       Date:  1994-09       Impact factor: 2.273

7.  Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors.

Authors:  H Daub; F U Weiss; C Wallasch; A Ullrich
Journal:  Nature       Date:  1996-02-08       Impact factor: 49.962

Review 8.  Tyrosine kinase pathways and the regulation of smooth muscle contractility.

Authors:  M D Hollenberg
Journal:  Trends Pharmacol Sci       Date:  1994-04       Impact factor: 14.819

Review 9.  Tyrosine kinase-mediated signal transduction pathways and the actions of polypeptide growth factors and G-protein-coupled agonists in smooth muscle.

Authors:  M D Hollenberg
Journal:  Mol Cell Biochem       Date:  1995 Aug-Sep       Impact factor: 3.396

10.  Evidence for the presence of a proteinase-activated receptor distinct from the thrombin receptor in vascular endothelial cells.

Authors:  J J Hwa; L Ghibaudi; P Williams; M Chintala; R Zhang; M Chatterjee; E Sybertz
Journal:  Circ Res       Date:  1996-04       Impact factor: 17.367

View more
  3 in total

1.  Smooth muscle contraction and growth of stromal cells in the human prostate are both inhibited by the Src family kinase inhibitors, AZM475271 and PP2.

Authors:  Yiming Wang; Christian Gratzke; Alexander Tamalunas; Beata Rutz; Anna Ciotkowska; Frank Strittmatter; Annika Herlemann; Sophie Janich; Raphaela Waidelich; Chunxiao Liu; Christian G Stief; Martin Hennenberg
Journal:  Br J Pharmacol       Date:  2016-11-01       Impact factor: 8.739

2.  GPCR-mediated EGF receptor transactivation regulates TRPV4 action in the vasculature.

Authors:  Mahmoud Saifeddine; Mahmoud El-Daly; Koichiro Mihara; Nigel W Bunnett; Peter McIntyre; Christophe Altier; Morley D Hollenberg; Rithwik Ramachandran
Journal:  Br J Pharmacol       Date:  2015-03-18       Impact factor: 8.739

Review 3.  Diversification of PAR signaling through receptor crosstalk.

Authors:  Irene Lee-Rivera; Edith López; Ana María López-Colomé
Journal:  Cell Mol Biol Lett       Date:  2022-09-10       Impact factor: 8.702

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.